NASDAQ:SRNE Sorrento Therapeutics - SRNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.96 0.00 (0.00%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.92▼$0.9850-Day Range$0.74▼$1.3852-Week Range$0.74▼$3.60Volume16.08 million shsAverage Volume11.34 million shsMarket Capitalization$453.00 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sorrento Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside837.5% Upside$9.00 Price TargetShort InterestBearish13.24% of Shares Sold ShortDividend StrengthN/ASustainability-1.05Upright™ Environmental ScoreNews Sentiment0.75Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector614th out of 1,053 stocksBiological Products, Except Diagnostic Industry97th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingSorrento Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Sorrento Therapeutics has a forecasted upside of 837.5% from its current price of $0.96.Amount of Analyst CoverageSorrento Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.24% of the outstanding shares of Sorrento Therapeutics have been sold short.Short Interest Ratio / Days to CoverSorrento Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Sorrento Therapeutics has recently increased by 1.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSorrento Therapeutics does not currently pay a dividend.Dividend GrowthSorrento Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSorrento Therapeutics has received a 73.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Glucocorticoids" products. See details.Environmental SustainabilityThe Environmental Impact score for Sorrento Therapeutics is -1.05. Previous Next 3.8 News and Social Media Coverage News SentimentSorrento Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Sorrento Therapeutics this week, compared to 2 articles on an average week.Social Mentions This WeekMarketBeat has tracked 1 reddit mention for Sorrento Therapeutics this week, compared to 0 mentions on an average week.Search Interest94 people have searched for SRNE on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.MarketBeat Follows70 people have added Sorrento Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sorrento Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Sorrento Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 34.48% of the stock of Sorrento Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sorrento Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.84) per share.Price to Book Value per Share RatioSorrento Therapeutics has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sorrento Therapeutics (NASDAQ:SRNE) StockSorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.Read More Receive SRNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRNE Stock News HeadlinesJanuary 14, 2023 | marketbeat.comMarketBeat: Week in Review 01/09-01/13 (SRNE)Markets are looking for direction in early trading before a holiday weekend. Here are some of the popular stories MarketBeat analysts were covering this week.January 12, 2023 | marketbeat.comSorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the MoveSorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to marketFebruary 2, 2023 | Investing Trends (Ad)The Biggest "Missing Ingredient" in the $7 Trillion EV MarketChina has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.February 2, 2023 | americanbankingnews.comHC Wainwright Weighs in on Sorrento Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:SRNE)February 2, 2023 | americanbankingnews.comSorrento Therapeutics (NASDAQ:SRNE) Price Target Cut to $13.00January 31, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sorrento Therapeutics (SRNE), Aethlon Medical (AEMD)January 29, 2023 | finance.yahoo.comScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common StockJanuary 29, 2023 | finance.yahoo.comSorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common StockFebruary 2, 2023 | Investing Trends (Ad)The Biggest "Missing Ingredient" in the $7 Trillion EV MarketChina has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.January 17, 2023 | reuters.comSRNE.A - | Stock Price & Latest News | ReutersJanuary 9, 2023 | finance.yahoo.comSorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BoostingJanuary 2, 2023 | nz.finance.yahoo.comSorrento Therapeutics, Inc. (SRNE)December 6, 2022 | finance.yahoo.comSorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 VirusDecember 5, 2022 | finance.yahoo.comSorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)November 29, 2022 | seekingalpha.comSorrento posts Phase 1 data for oral COVID therapyNovember 29, 2022 | finance.yahoo.comSorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BoostingNovember 18, 2022 | finance.yahoo.comFurther weakness as Sorrento Therapeutics (NASDAQ:SRNE) drops 12% this week, taking one-year losses to 76%November 13, 2022 | tmcnet.comSorrento to Host Webcast to Discuss Newly PresentedNovember 13, 2022 | finance.yahoo.comSorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid ArthritisNovember 10, 2022 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business CombinationNovember 10, 2022 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”November 9, 2022 | seekingalpha.comSorrento: Limited Potential, High Management Compensation, Complicated LawsuitsNovember 9, 2022 | apnews.comSorrento Therapeutics: Q3 Earnings SnapshotNovember 8, 2022 | seekingalpha.comSorrento Therapeutics: Down The Rabbit HoleOctober 28, 2022 | finance.yahoo.com7 of the Best Contrarian Stocks to Buy When Investors Are FearfulOctober 21, 2022 | finance.yahoo.comSorrento Therapeutics, Inc. stock performance and analyst projectionsOctober 20, 2022 | finance.yahoo.comWhy Sorrento Therapeutics Stock Is on the Rise TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRNE Company Calendar Last Earnings11/08/2022Today2/02/2023Next Earnings (Estimated)2/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRNE CUSIPN/A CIK850261 Webwww.sorrentotherapeutics.com Phone(858) 203-4100Fax858-210-3759Employees799Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,202.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-428,330,000.00 Net Margins-818.22% Pretax Margin-877.48% Return on Equity-282.82% Return on Assets-57.64% Debt Debt-to-Equity Ratio0.14 Current Ratio0.88 Quick Ratio0.79 Sales & Book Value Annual Sales$52.90 million Price / Sales8.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book3.69Miscellaneous Outstanding Shares471,880,000Free Float459,611,000Market Cap$453.00 million OptionableOptionable Beta1.95 Key ExecutivesHenry H. JiChairman, President & Chief Executive OfficerShawn SahebiSenior Vice President-Commercial OperationsElizabeth Adkins CzerepakChief Financial Officer & Executive Vice PresidentMike A. RoyalChief Medical OfficerRobert D. AllenSenior Vice President-Research & DevelopmentKey CompetitorsCaribou BiosciencesNASDAQ:CRBUIcosavaxNASDAQ:ICVXKodiak SciencesNASDAQ:KODSutro BiopharmaNASDAQ:STROAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsMayo ClinicBought 300,000 shares on 1/26/2023Ownership: 0.064%Donald L. Hagan LLCBought 20,037 shares on 1/17/2023Ownership: 0.036%Collective Family Office LLCBought 13,500 shares on 1/11/2023Ownership: 0.025%Weaver Consulting GroupBought 35,500 shares on 1/9/2023Ownership: 0.010%GoalVest Advisory LLCBought 18,025 shares on 1/6/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions SRNE Stock - Frequently Asked Questions Should I buy or sell Sorrento Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRNE shares. View SRNE analyst ratings or view top-rated stocks. What is Sorrento Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 12-month target prices for Sorrento Therapeutics' stock. Their SRNE share price forecasts range from $5.00 to $13.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 837.5% from the stock's current price. View analysts price targets for SRNE or view top-rated stocks among Wall Street analysts. How have SRNE shares performed in 2023? Sorrento Therapeutics' stock was trading at $0.8860 on January 1st, 2023. Since then, SRNE shares have increased by 8.4% and is now trading at $0.96. View the best growth stocks for 2023 here. When is Sorrento Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023. View our SRNE earnings forecast. How were Sorrento Therapeutics' earnings last quarter? Sorrento Therapeutics, Inc. (NASDAQ:SRNE) announced its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biopharmaceutical company had revenue of $17.40 million for the quarter, compared to analyst estimates of $11.69 million. Sorrento Therapeutics had a negative net margin of 818.22% and a negative trailing twelve-month return on equity of 282.82%. What other stocks do shareholders of Sorrento Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO). What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mayo Clinic (0.06%), Donald L. Hagan LLC (0.04%), Collective Family Office LLC (0.03%), GoalVest Advisory LLC (0.01%), Weaver Consulting Group (0.01%) and Bank of Montreal Can (0.00%). Insiders that own company stock include Henry Ji, Kim Janda and Robin L Smith. View institutional ownership trends. How do I buy shares of Sorrento Therapeutics? Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $0.96. How much money does Sorrento Therapeutics make? Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $453.00 million and generates $52.90 million in revenue each year. How many employees does Sorrento Therapeutics have? The company employs 799 workers across the globe. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759. This page (NASDAQ:SRNE) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.